NEXSTAR CANCELS OFFERING AMIDST PATENT INFRINGEMENT CLAIMS OVER AMBISOME
NeXstar's cancellation of a 2.5 mil. share offering may be the first sign that the current biotech financing boom is drawing to a close
You may also be interested in...
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.